MK
Therapeutic Areas
Buzzard Pharmaceutical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Isunakinra | Microsatellite Stable, KRAS-mutated Colorectal Cancer | Phase 2A |
Leadership Team at Buzzard Pharmaceutical
MD
Maarten de Château
Chief Executive Officer
CN
Chris Nowak
Chief Medical Officer
HO
Hans Olivecrona
Chief Scientific Officer